MDXG News and Press, MiMedx Group Inc From 02/28/23

MiMedx Group press release ( NASDAQ: MDXG ): Q4 GAAP EPS of -$0.02. Revenue of $74.38M (+10.4% Y/Y). For further details see: MiMedx Group GAAP EPS of -$0.02, revenue of $74.38M

Reports Highest Quarterly Net Sales Since the Fourth Quarter of 2019 Quarterly Net Sales of $74.4 million Reflect Growth of 10% with Strong Contributions from Sales to the Surgical Market Initiated the First of Two Registrational Clinical Trials for micronized d...

MARIETTA, Ga., Feb. 15, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a pioneer and leader in placental biologics, today announced that it will report operating and financial results for the fourth quarter and full year ended D...

Wound care company MiMedx Group ( NASDAQ: MDXG ) said on Monday that Joseph Capper, a MedTech and Life Sciences veteran with a track record in M&A, has been appointed as its chief executive officer with immediate effect. Todd Newton, who has functioned as the company’s inte...

Highly experienced and accomplished three-time healthcare CEO with a proven track record of substantial value creation to lead MIMEDX MARIETTA, Ga., Jan. 30, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a pioneer and lea...

MiMedx ( NASDAQ: MDXG ) said it continues to expect Q4 net sales to be in the ranges of $73M to $76M vs. estimates of $74.53M The company also continues to expect full year revenue of $266M to $269M vs. $268M consensus, which remains unchanged from the outlook provided during the ...

Fourth quarter and full year 2022 net sales expected in the ranges of $73 million to $76 million and $266 million to $269 million, respectively Provides commentary regarding the potential impact of recently published Medicare reimbursement proposals on its wound care products MARI...

MiMedx Group ( NASDAQ: MDXG ) on Wednesday said it had entered into an exclusive distribution agreement with Japan's Gunze Medical for sales of its EPIFIX product. MDXG stock gained 7.3% to $3.22 after hours. MDXG's EPIFIX is a placental tissue allograft that can be used t...

MIMEDX aligns with a leading distributor of wound care products in Japan to capitalize on first-mover advantage for EPIFIX MARIETTA, Ga. and OSAKA, Japan, Jan. 04, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a pioneer...

MiMedx Group ( NASDAQ: MDXG ) has appointed Ricci S. Whitlow as COO. Most recently she served as President, Clinical Supply Services at Catalent. For further details see: MiMedx appoints Ricci S. Whitlow as Chief Operating Officer